DiscoverGSA Momentum DiscussionsStimulating Early Neurology Referrals for People with Cognitive Impairment Who May Benefit from Anti-Amyloid Therapies
Stimulating Early Neurology Referrals for People with Cognitive Impairment Who May Benefit from Anti-Amyloid Therapies

Stimulating Early Neurology Referrals for People with Cognitive Impairment Who May Benefit from Anti-Amyloid Therapies

Update: 2025-02-04
Share

Description

In this Momentum Discussion Podcast episode, Dr. Armen J. Moughamian, a neurologist who cares for people with neurodegenerative brain illnesses, including Alzheimer’s disease and other dementias, explains anti-amyloid therapy for Alzheimer’s disease and mild cognitive impairment. He describes who may benefit from these therapies, discusses their efficacy and safety, and explains the importance of early detection of cognitive impairment. Dr. Moughamian also provides important insights into how primary care teams can help ensure that individuals who might be candidates for anti-amyloid therapies are well prepared for timely referrals to a neurologist.


Download the Transcript


Speaker


Armen J. Moughamian, MD, PhD, Medical Director at the Ray Dolby Brain Health Center, Division Chief of Neurology, Vice Chair of Neuroscience at the California Pacific Medical Center


Host


Jennifer L. Pettis, MS, RN, CNE, Director, Strategic Alliances, Gerontological Society of America


 


This podcast episode is supported by Eisai. Content was developed by Gerontological Society of America (GSA).

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Stimulating Early Neurology Referrals for People with Cognitive Impairment Who May Benefit from Anti-Amyloid Therapies

Stimulating Early Neurology Referrals for People with Cognitive Impairment Who May Benefit from Anti-Amyloid Therapies

The Gerontological Society of America